Bioxytran’s Cancer Preprint Reveals Potential to Enhance Most Immunotherapy Drugs
10. Januar 2025 10:21 ET
|
BIOXYTRAN, INC.
BOSTON, MASSACHUSETTS, Jan. 10, 2025 (GLOBE NEWSWIRE) -- BIOXYTRAN, INC. (OTCQB: BIXT) (the “Company”), a clinical stage biotechnology company developing oral and intravenous drugs to treat viral...